Beclometasone dipropionate
Soprobec inhalation aerosol, solution is used for the preventionof asthma symptoms. The active substance, beclometasone dipropionate, belongs to a group of medicines called corticosteroids, which are often referred to as steroids. Steroids have anti-inflammatory effects, reducing swelling and irritation in the walls of the small airways in the lungs and making it easier to breathe.
Before starting treatment with Soprobec, discuss with your doctor, pharmacist or nurse:
You should also discuss with your doctor, pharmacist or nurse if the following situations apply to the patient:
If the patient is using high doses of inhaled steroids for a long time and finds themselves in a stressful situation, they may need to be given a steroid medicine in the form of tablets or injections. For example, when admitted to hospital after a serious accident, before surgery, during an acute asthma attack, or if the patient has a respiratory infection, or after another serious illness. The doctor will decide whether additional steroid treatment is necessary and advise how long to take the steroid tablets and how to reduce the dose if the patient feels better.
If the patient experiences blurred vision or other vision disturbances, they should contact their doctor.
Before starting treatment, tell your doctor about all medicines you are currently taking or have recently taken, as well as any medicines you plan to take, including those available without a prescription.
Tell your doctor if you are taking disulfiram or metronidazole, due to the possible risk of interaction, especially in sensitive individuals.
Remember to take this medicine and the inhaler with you if you need to go to the hospital.
Some medicines may enhance the effect of Soprobec, and your doctor may advise careful monitoring of your health if you are taking such medicines (including some HIV medicines: ritonavir, cobicistat).
If the patient is pregnant or breastfeeding, thinks they may be pregnant or plans to have a child, they should consult their doctor or pharmacist before using this medicine.
It is unlikely that Soprobec will affect your ability to drive or use machines.
This medicine contains 7.47 mg (50 micrograms and 100 micrograms strength), 8.05 mg (200 micrograms strength) and 8.62 mg (250 micrograms strength) of alcohol (ethanol) per dose, which is equivalent to 13% w/w (50 micrograms and 100 micrograms strength), 14% w/w (200 micrograms strength) and 15% w/w (250 micrograms strength). The amount of alcohol in each dose of this medicine is equivalent to less than 4 ml of beer or 2 ml of wine. The small amount of alcohol in this medicine will not have noticeable effects.
Soprobec is available in 4 different strengths. The doctor will determine the appropriate strength of the medicine for the patient. The 200 micrograms and 250 micrograms strengths are not suitable for children.
The inhaler should always be used as directed by the doctor or pharmacist. If you have any doubts, consult your doctor or pharmacist. The instructions for using the inhaler are in the section on dosage. It may take a few days for the medicine to start working, so it is essential to use it regularly.
Do not stoptreatment, even if you feel better, unless your doctor advises you to. Do notsuddenly stopusing the inhaler.
While using Soprobec, your doctor may regularly assess your asthma symptoms by performing a simple test to assess lung function and ordering blood tests from time to time.
The initial dose will be determined by the doctor, depending on the severity of the asthma symptoms. It may be higher than the dose given below. The doctor will prescribe the smallest dose of Soprobec that will control the symptoms.
A device known as a Volumatic inhalation chamber should always be used:
The usual initial dose is:
Adults and the elderly:
200 micrograms (4 puffs) twice a day
Children:
100 micrograms (2 puffs) twice a day
The usual maximum daily dose is:
Adults and the elderly:
800 micrograms (16 puffs)
Children:
400 micrograms (8 puffs)
The total daily dose can be divided into 2, 3 or 4 doses per day.
The usual initial dose is:
Adults and the elderly:
200 micrograms (2 puffs) twice a day
Children:
100 micrograms (1 puff) twice a day
The usual maximum daily dose is:
Adults and the elderly:
800 micrograms (8 puffs)
Children:
400 micrograms (4 puffs)
The total daily dose can be divided into 2, 3 or 4 doses per day.
The usual initial dose is:
Adults and the elderly:
200 micrograms (1 puff) twice a day
The usual maximum daily dose is:
800 micrograms (4 puffs)
The total daily dose can be divided into 2, 3 or 4 doses per day.
The usual initial dose is:
Adults and the elderly:
500 micrograms (2 puffs) twice a day
The usual maximum daily dose is:
2000 micrograms (8 puffs)
The total daily dose can be divided into 2, 3 or 4 doses per day.
Tell your doctor as soon as possible. The doctor may advise a blood test to measure the level of cortisol in the patient's blood and therefore may advise a blood test (cortisol is a steroid hormone that occurs naturally in the body).
It is essential to use the dose as advised by the doctor. Do not increase or decrease the dose of the medicine without consulting your doctor.
Do not take a double dose to make up for a missed dose. Take the next dose at the right time. Do not take more puffs than prescribed.
Soprobec is for inhalation use.
It is essential that the patient knows how to use the inhaler correctly. The doctor, nurse or pharmacist will instruct the patient on how to use the inhaler and will regularly check that the patient is using it correctly. Follow the instructions carefully so that the patient knows how when and how manypuffs of the medicine to use and how long to use the inhaler. If you have any doubts about using the inhaler or inhalation, consult your doctor, nurse or pharmacist for help.
Checking the inhaler:If the inhaler is new or has not been used for at least 3 days, you should release one puff away from you (into the air) to check that it is working.
Important: The steps described in points 2, 3, 4 and 5 should not be performed too quickly.
It is essential to start breathing in as slowly as possible, just before activating the inhaler. Before using the inhaler for the first time, practice these steps in front of a mirror.
If the patient notices a "mist" coming out of the top of the inhaler or the sides of the mouth,
this means that the medicine is not getting into the lungs as it should. Take another puff, following the instructions from step 2.
If patients have weak hands or the inhaler is being used by children, it may be easier for them to hold the inhaler with both hands. Place your index fingers on the top of the inhaler and your thumbs on the bottom of the inhaler under the mouthpiece.
If the patient finds it difficult to use the inhaler while breathing in, they may use a Volumatic inhalation chamber. Consult your doctor, pharmacist or nurse about this device.
However, the Volumatic inhalation chamber should always be used if:
Young children may find it difficult to use the inhaler correctly and may need help. In children under 5, using the inhaler with a Volumatic inhalation chamber and a face mask may be helpful. Consult your doctor, nurse or pharmacist if the patient has any difficulties.
It is essential to clean the inhaler at least once a week to prevent it from becoming blocked.
It is essential to read the leaflet accompanying the Volumatic inhalation chamber and follow the instructions for its use and cleaning carefully.
Like all medicines, Soprobec can cause side effects, although not everybody gets them.
The following side effects have been reported. If the patient experiences any side effects, tell your doctor as soon as possible, but do not stoptreatmentunless your doctor advises you to. To prevent side effects, the doctor will prescribe the smallest possible dose of Soprobec to control the asthma symptoms.
If the patient feels worseor experiences symptoms such as loss of appetite, abdominal pain, weight loss, fatigue, nausea (vomiting), feels weak, sweats, and trembles, they should contact their doctor. This is especially important if the patient is in a stressful situation, such as surgery, infection, acute asthma attack, or another serious illness.
The doctor may advise blood tests from time to time to measure the level of steroids in the patient's body.
If you experience any side effects, including any side effects not listed in the leaflet, tell your doctor, pharmacist or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309,
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Warning:The canister contains a pressurized liquid. Store away from heat sources and protect from direct sunlight, do not expose to high temperatures (above 50°C) and do not pierce or burn, even after use.
The active substance of the inhaled medicine is beclometasone dipropionate. Each delivered dose contains 50, 100, 200 or 250 micrograms of beclometasone dipropionate.
The other ingredients are: glycerol, anhydrous ethanol and norfluran (HFC-134a).
This medicine contains fluorinated greenhouse gases.
Soprobec, 50 micrograms:
Each inhaler contains 11.808 g HFC-134a, which is equivalent to 0.017 tons of CO2 equivalent (GWP = 1430)
Soprobec, 100 micrograms:
Each inhaler contains 11.796 g HFC-134a, which is equivalent to 0.017 tons of CO2 equivalent (GWP = 1430)
Soprobec, 150 micrograms:
Each inhaler contains 11.634 g HFC-134a, which is equivalent to 0.017 tons of CO2 equivalent (GWP = 1430)
Soprobec, 200 micrograms:
Each inhaler contains 11.484 g HFC-134a, which is equivalent to 0.016 tons of CO2 equivalent (GWP = 1430)
Soprobec 50 micrograms/dose is an inhalation aerosol solution in an aluminum pressurized canister with a cream-colored plastic inhaler and a dark brown protective cap. Each carton contains one inhaler or two inhalers. Each canister contains 200 doses (puffs).
Soprobec 100 micrograms/dose is an inhalation aerosol solution in an aluminum pressurized canister with a gray plastic inhaler and a light pink protective cap. Each carton contains one inhaler or two inhalers. Each canister contains 200 doses (puffs).
Soprobec 200 micrograms/dose is an inhalation aerosol solution in an aluminum pressurized canister with a pink plastic inhaler and a red protective cap. Each carton contains one inhaler or two inhalers. Each canister contains 200 doses (puffs).
Soprobec 250 micrograms/dose is an inhalation aerosol solution in an aluminum pressurized canister with a burgundy-colored plastic inhaler and a gray protective cap. Each carton contains one inhaler or two inhalers. Each canister contains 200 doses (puffs).
Not all pack sizes may be marketed.
Glenmark Pharmaceuticals s.r.o.
Hvězdova 1716/2b
140 78 Prague 4
Czech Republic
Glenmark Pharmaceuticals Europe Limited
Building 2, Croxley Green Business Park
Croxley Green, WD18 8YA Hertfordshire
United Kingdom
Glenmark Pharmaceuticals s.r.o.
Fibichova 143
566 17 Vysoké Mýto
Czech Republic
Synoptis Industrial Sp. z o.o.
ul. Rabowicka 15
62-020 Swarzędz
Poland
Glenmark Pharmaceuticals Sp. z o.o.
ul. Osmańska 14
02-823 Warsaw
Country | Medicinal product name |
United Kingdom | Soprobec 50/100/200/250 micrograms per actuation pressurised inhalation solution |
Czech Republic | Soprobec |
Denmark | Soprobec 50/100/200/250 micrograms per actuation pressurised inhalation solution |
Finland | Soprobec 50/100/200/250 micrograms per actuation pressurised inhalation solution |
Germany | Beclometason Glenmark Dosieraerosol 50/100/200/250 Mikrogramm/Sprühstoß Druckgasinhalation, Lösung |
Italy | BECLOMETASONE DOC Generici |
Netherlands | Soprobec 50/100/200/250 microgram/dosis aërosol, oplossing |
Norway | Soprobec |
Poland | Soprobec |
Romania | Soprobec 50/100/200/250 micrograme pe doză soluţie de inhalat presurizată |
Slovakia | Soprobec 50/100/200/250 micrograms per actuation pressurised inhalation solution |
Spain | Soprobec 50/100/200/250 microgramos/inhalación, solución para inhalación en envase a presión |
Sweden | Soprobec 50/100/200/250 micrograms/actuation pressurised inhalation, solution |
Date of last revision of the leaflet:December 2024
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.